Search
元素の検索
構造の検索
Thermo Scientific Chemicals
Candesartan, 98%
Angiotensin II receptor antagonist | CAS: 139481-59-7 | C24H20N6O3 | 440.463 g/mol
化学物質識別子
CAS139481-59-7
仕様
スペックシート
スペックシートAssay from Supplier's CofA≥97.5%
Appearance (Color)White to pale cream
FormPowder
Infrared spectrumConforms
Melting Point176-185°C
Candesartan is a selective AT1 (angiotensin II receptor 1) antagonist. Antagonism of angiotensin receptors inhibits vasoconstriction and the production of aldosterone, leading to a decrease in water and sodium concentration in blood plasma. Exhibits antihypertensive effects in animal models. Used in treatment of congestive heart failure, as antihypertensive. Candesartan does not affect cell viability or proliferation but increases the expression of VEGF and interleukin-8 in the cultured medium of KU-19-19 cells. Candesartan (0.1 nM) could reduce the maximal contractile response to angiostensin II by approximately 50%.
This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
Solubility
Soluble in ethyl acetate, methanol, water (<1mg/mL at 25°C), DMSO (88 mg/ml at 25°C), and ethanol (1 mg/ml at 25°C).
Notes
Store away from oxidizing agents. Keep the container tightly closed and place it in a cool, dry and well ventilated condition.
Soluble in ethyl acetate, methanol, water (<1mg/mL at 25°C), DMSO (88 mg/ml at 25°C), and ethanol (1 mg/ml at 25°C).
Notes
Store away from oxidizing agents. Keep the container tightly closed and place it in a cool, dry and well ventilated condition.
RUO – Research Use Only
General References:
- Kaur N, et al. Design, synthesis, and evaluation of 5-sulfamoyl benzimidazole derivatives as novel angiotensin II receptor antagonists.Bioorg Med Chem.,2008,16(24), 10210-5.
- Nishikawa K, et al. Candesartan cilexetil: a review of its preclinical pharmacology.J Hum Hypertens.,1997,29-17.